Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 7 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Intra-cellular Therapies Inc. is currently managing 10 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 10 distinct examiners, showing a high level of diversification for the portfolio's personnel. The involvement of 7 distinct art units further indicates that the company's research is being evaluated across several specialized biological and pharmaceutical fields. This distribution helps mitigate the risk associated with any single examiner's interpretation or departmental standard.
The busiest examiner, KIFLE, BRUCK, is responsible for 1 pending office action, which is consistent with the decentralized nature of the 10 pending office actions currently active. This comparison between the 1 action handled by the busiest examiner and the 10 pending office actions total highlights that the portfolio is not concentrated in the hands of a few individuals. With 10 distinct examiners and 7 distinct art units engaged, the company is navigating a variety of technical standards. The busiest examiner's limited role ensures that the overall success of the Biotechnology & Pharmaceuticals portfolio depends on a wide range of examiner reviews.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (30%) |
| §112 only | 2 (20%) |
| Double-patenting only | 2 (20%) |
| Double-patenting + other | 2 (20%) |
| Multi-statute (no §101) | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| SCHMITT, MICHAEL J | 1 | 57.0% | +20.4% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +39.1% |
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| JAVANMARD, SAHAR | 1 | 64.9% | +34.1% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
| SHOWALTER, ALEXANDER KEITH | 1 | 55.4% | +27.3% |
| LEE, ANDREW P | 1 | 48.5% | +22.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18866978 | NOVEL METHODS | KIFLE, BRUCK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007018 | NOVEL USES | SHOWALTER, ALEXANDER KEITH | 60d overdue |
| 18042103 | ORGANIC COMPOUNDS | FETTEROLF, BRANDON J | 3d overdue |
| 18866978 | NOVEL METHODS | KIFLE, BRUCK | — |
| 18847126 | ORGANIC COMPOUNDS | SCHMITT, MICHAEL J | — |
| 18847121 | ORGANIC COMPOUNDS | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| 18670391 | NOVEL METHODS | JAVANMARD, SAHAR | — |
| 18481168 | NOVEL METHODS | RODRIGUEZ-GARCIA, VALERIE | — |
| 18320173 | NOVEL METHODS | CHONG, YONG SOO | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1622 | 2 |
| 1691 | 2 |
| 1624 | 1 |
| 1600 | 1 |
| 1623 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866978 | NOVEL METHODS | KIFLE, BRUCK | 1624 | §103§112 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18847126 | ORGANIC COMPOUNDS | SCHMITT, MICHAEL J | 1629 | §112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18847121 | ORGANIC COMPOUNDS | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103§112DP | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18777765 | NOVEL METHODS | SHIAO, REI TSANG | 1691 | DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18670391 | NOVEL METHODS | JAVANMARD, SAHAR | 1622 | §112Other | Non-Final OA | — | Pending | May 21, 2024 |
| 18481168 | NOVEL METHODS | RODRIGUEZ-GARCIA, VALERIE | 1600 | §103DP | Final Rejection | — | Pending | Oct 04, 2023 |
| 18320173 | NOVEL METHODS | CHONG, YONG SOO | 1623 | DP | Final Rejection | — | Pending | May 18, 2023 |
| 18042103 | ORGANIC COMPOUNDS | FETTEROLF, BRANDON J | 1626 | §103 | Non-Final OA | 3d overdue | Pending | Feb 17, 2023 |
| 18007018 | NOVEL USES | SHOWALTER, ALEXANDER KEITH | 1629 | §103 | Non-Final OA | 60d overdue | Pending | Jan 26, 2023 |
| 17127867 | METHODS OF SCHIZOPHRENIA TREATMENT | LEE, ANDREW P | 1691 | §103 | Final Rejection | — | Pending | Dec 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIntra-cellular Therapies Inc. has 10 pending office actions as of October 2026, spread across 7 art units and 10 examiners.
Bruck Kifle has the most, with 1 of Intra-cellular Therapies Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
